Most Read Articles
Jairia Dela Cruz, 20 Jan 2018
Empagliflozin appears to be beneficial to type 2 diabetes (T2D) patients with established cardiovascular disease (CVD) and chronic kidney disease (CKD), yielding reductions in CV and all-cause mortality, as well as in heart failure and all-cause hospitalization compared with placebo, according to a study.
13 Feb 2018
Short-term treatment with methotrexate at >0.5 defined daily dose (8.75 mg/week) may help reduce the risk of ischaemic stroke in rheumatoid arthritis (RA) patients, while hydroxychloroquine and sulfasalazine have neutral effects, a retrospective study has found.
28 Dec 2017
Varenicline, while effective for smoking cessation, appears to significantly elevate the risk of cardiovascular hospitalization and emergency department visits, particularly for new users, a recent study shows.
29 Nov 2017
Younger children appear to be more likely to experience behavioural side effects of antiepileptic drugs (AEDs), with the likelihood increasing if children with epilepsy have baseline hyperactivity/impulsivity, a retrospective study has found.

CGM tied to reduced time spent in hypoglycaemia in patients with T1D

Elaine Soliven
02 Oct 2017

The use of continuous glucose monitoring (CGM) is associated with a decreased amount of time spent in hypoglycaemia in patients with type 1 diabetes (T1D), according to a study presented at EASD 2017.

This randomized crossover study analysed 161 adults with T1D (mean age 43.7 years, 45.3 percent women, mean HbA1c 70 mmol/L) who were treated with multiple daily insulin (MDI) injections. Participants were randomized to start either CGM treatment (Dexcom G4 device) or self-measurement of blood glucose (SMBG) treatment for 26 weeks, followed by a washout period of 17 weeks before crossing over to the other treatment for another 26 weeks. [EASD 2017, abstract 715]

Overall, participants spent significantly less time in hypoglycaemia (<3.9 mmol/L) during CGM treatment than during the SMBG treatment (2.8 percent vs 4.8 percent). Participants with HbA1c <3 mmol/L also had a reduced time spent in hypoglycaemia with CGM vs SMGB treatment (0.8 percent vs 1.9 percent).

When the analysis was stratified by HbA1c level, a significant reduction in time spent in hypoglycaemia was observed with CGM treatment compared with SMBG treatment during daytime (from 6:00 am to 11:59 pm, 49 vs 30 minutes) and nighttime (from midnight to 5:59 am, 19 vs 10 minutes) among participants with HbA1c <3.9 mmol/L.

Among participants with HbA1c <3 mmol/L, time spent in hypoglycaemia was also reduced in the CGM vs the SMGB arms (8 vs 18 minutes at daytime and 3 vs 9 minutes at nighttime).

“The improvement in time spent in hypoglycaemia disappeared when CGM was not used,” according to lead author Arndis Olafsdottir, a registered nurse and junior researcher from the Department of Molecular and Clinical Medicine at the University of Gothenburg, Sweden.

Based on the Hypoglycaemic Confidence Scale (HCS) responses, the patients’ confidence in managing a hypoglycaemic episode significantly improved during CGM treatment, with an improvement in HCS score from 3.27 to 3.4.

In addition, significant improvements were noted in four out of the nine items in HCS, with most patients expressing confidence in identifying and managing a hypoglycaemic event before it occurs (p=0.0033), avoiding serious hypoglycaemic complications in general (p=0.002) or in social settings (p=0.016), and carrying on with their duties despite the risk of hypoglycaemia (p=0.022).

“[Overall,] CGM [treatment] reduces time spent in nocturnal and daytime hypoglycaemia in T1D adults on MDI. CGM also increases confidence in avoiding hypoglycaemia and problems related to them,” Olafsdottir added.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 20 Jan 2018
Empagliflozin appears to be beneficial to type 2 diabetes (T2D) patients with established cardiovascular disease (CVD) and chronic kidney disease (CKD), yielding reductions in CV and all-cause mortality, as well as in heart failure and all-cause hospitalization compared with placebo, according to a study.
13 Feb 2018
Short-term treatment with methotrexate at >0.5 defined daily dose (8.75 mg/week) may help reduce the risk of ischaemic stroke in rheumatoid arthritis (RA) patients, while hydroxychloroquine and sulfasalazine have neutral effects, a retrospective study has found.
28 Dec 2017
Varenicline, while effective for smoking cessation, appears to significantly elevate the risk of cardiovascular hospitalization and emergency department visits, particularly for new users, a recent study shows.
29 Nov 2017
Younger children appear to be more likely to experience behavioural side effects of antiepileptic drugs (AEDs), with the likelihood increasing if children with epilepsy have baseline hyperactivity/impulsivity, a retrospective study has found.